⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Glioblastoma Multiforme Market Intelligence Report 2026-2030 & 2035: Advanced Targeted Drugs Propel Industry Growth
globenewswire.com
PFE
ABBV
BMY
AZN
MRK
Head and Neck Squamous Cell Carcinoma Market Forecast to 2030 & 2035
globenewswire.com
EXEL
MRK
PFE
BMY
AZN
NCCN Foundation Announces Annual Awards to Support Future Leaders for Cancer Innovation
prnewswire.com
EXEL
MRK
PFE
Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth
globenewswire.com
NVCR
MRK
PFE
ABBV
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
businesswire.com
MRK
Medulloblastoma Drugs Market Analysis and Growth Forecast 2026-2030 & 2035 by Drug Candidate, Product, Route of Administration, Distribution Channel, End-user and Region
globenewswire.com
PFE
NVS
BMY
MRK
AZN
European Commission Approves KEYTRUDA ® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
businesswire.com
MRK
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate
globenewswire.com
UTHR
PFE
AMGN
JNJ
ABBV
MRK
BMY
MAC
Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players
globenewswire.com
NVCR
MRK
PFE
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
businesswire.com
ABBV
MRK